CD79A and COVID-19: There was no change in IgG or IgM levels in the blood throughout the study period in both test groups, but an increase in IgA levels along with the decrease in D-dimer by AFO-202 and of galectin, fibrinogen, and ferritin by the combination of AFO-202 and N-163 beta glucan (Group II) offers evidence in favour of the combined approach for addressing immune associated coagulopathy-associated risks in diseases such as COVID-19, in which a hyperactivated immune response affects the clotting pathway (13).